Bedrijfsoverzicht
BioRestorative Therapies, Inc. is a biotechnology entity focused on the development of therapeutic products and medical therapies that utilize specific cell and tissue protocols, primarily centered on adult stem cells for treating disc and spine diseases as well as metabolic disorders. Operating within the broader Healthcare sector and the specialized Biotechnology industry, the company aims to advance medical solutions through its proprietary pipeline of BRTX-100 and related programs. As of the latest available data, the organization maintains a market capitalization of $6.13M and employs 13 individuals to execute its research and development strategy. The company's annual revenue stands at $359,700, a figure that, when viewed against a market cap of $6.13M, indicates that the equity value significantly exceeds the current run-rate of sales, reflecting the high-risk, high-potential nature typical of early-stage biotechnology firms where valuation is driven by pipeline potential rather than current profitability.
Financiële gezondheid
The company reported a revenue of $359,700 over the trailing twelve months, yet this generated a net income of $-14,241,975, revealing a substantial gap that underscores a cost structure dominated by high operating expenses relative to current sales volume. The EBITDA for the same period was $-15,437,147, further highlighting that the business is currently burning cash rather than generating operational profit. Free cash flow stands at $-6,200,023, which indicates that the company is utilizing its liquid reserves to fund ongoing development and operations rather than returning capital or investing in mature assets. Profitability metrics are stark, with a profit margin of 0.0%, a gross margin of 93.4% that suggests high billing rates on sales, but an operating margin of -19516.8% that exposes the severe disconnect between revenue generation and cost containment in this growth phase. In terms of liquidity and leverage, the company holds $2.95M in cash against $42,282 in debt, resulting in a debt-to-equity ratio of 11.85 which signifies a highly leveraged balance sheet relative to its equity base, though the absolute debt amount is small. The current ratio is 0.84, indicating that current assets are slightly less than current liabilities, which suggests a tight short-term liquidity position that requires careful management of cash outflows. Return on equity is -320.5% and return on assets is -119.6%, metrics that reveal that management effectiveness, measured by traditional return metrics, is currently negative as the company consumes capital to pursue its long-term clinical and technological objectives.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is listed as N/A due to the negative earnings, while the forward P/E is calculated at -0.46, a negative multiple that implies the market is not pricing in immediate earnings recovery but rather views the stock based on other fundamental drivers or potential future profitability. The price-to-book ratio is 6.17, indicating that the market values the company at more than six times its book value, which suggests a significant premium assigned to the intangible assets and potential value of the development pipeline that are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 17.04 and an EV/EBITDA of -0.21 further illustrate that the company is priced on revenue multiples and enterprise value metrics that are common for pre-revenue or loss-making biotech companies where future commercial success is the primary valuation driver. The stock has traded between a 52-week high of $2.04 and a 52-week low of $0.19, with the current valuation context suggesting a price position that requires analysis relative to this wide historical range to determine if the asset is undervalued or overvalued based on pipeline milestones. The beta of 0.27 indicates that the stock exhibits low volatility relative to the broader market, moving significantly less than the benchmark index, which implies a lower correlation with general market swings but also potentially lower liquidity and higher idiosyncratic risk.
Growth & Income
Revenue growth year-over-year is -54.7%, while earnings growth is N/A due to the lack of positive earnings history, meaning the company is currently contracting in revenue terms rather than expanding its sales base. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute income to shareholders and instead reinvests all available capital back into its research, development, and operational capabilities to attempt to achieve profitability. The overall growth and income profile is characterized by significant revenue contraction and a complete absence of current income generation, relying entirely on the successful execution of its therapeutic pipeline to eventually transition to a growth and profit-generating phase. This financial structure reflects a classic early-stage biotechnology model where current metrics are negative, and the value proposition is contingent upon future clinical successes and market adoption of its stem cell therapies.